Consolidated Statement Of Cash Flows

Chiome Bioscience Inc. - Filing #7295173

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2021-12-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-1,215,008,000 JPY
-1,237,861,000 JPY
Depreciation
1,203,000 JPY
1,476,000 JPY
Subtotal
-1,071,232,000 JPY
-1,208,689,000 JPY
Decrease (increase) in trade receivables
32,024,000 JPY
-89,761,000 JPY
Income taxes paid
-5,010,000 JPY
-3,240,000 JPY
Decrease (increase) in inventories
7,371,000 JPY
-12,488,000 JPY
Increase (decrease) in trade payables
5,869,000 JPY
2,056,000 JPY
Net cash provided by (used in) operating activities
-1,069,192,000 JPY
-1,191,009,000 JPY
Other, net
42,928,000 JPY
-23,730,000 JPY
Interest paid
-2,069,000 JPY
-1,323,000 JPY
Cash flows from investing activities
Proceeds from sale of property, plant and equipment
173,000 JPY
JPY
Net cash provided by (used in) investing activities
173,000 JPY
JPY
Cash flows from financing activities
Proceeds from issuance of shares
554,515,000 JPY
1,126,292,000 JPY
Net cash provided by (used in) financing activities
667,303,000 JPY
1,127,291,000 JPY
Other, net
0 JPY
0 JPY
Net increase (decrease) in cash and cash equivalents
-401,715,000 JPY
-63,717,000 JPY
Cash and cash equivalents
1,325,554,000 JPY
1,727,270,000 JPY
1,790,988,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.